PTC Therapeutics, Inc. (PTCT)

PTC Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,765	806.78	937.82	698.8	538.59	380.77
Revenue Growth (YoY)	96.00%	-13.97%	34.20%	29.75%	41.45%	24.04%
Cost of Revenue	559.56	591.88	732.05	696.17	573.01	442.99
Gross Profit	1,205	214.9	205.77	2.63	-34.42	-62.22
Selling, General & Admin	324.36	300.91	332.54	326	285.77	244.46
Operating Expenses	338.56	361.65	555.18	442.55	340.52	281.36
Operating Income	866.81	-146.75	-349.4	-439.93	-374.94	-343.58
Interest Expense	-167.32	-170.39	-128.88	-90.87	-86.02	-56.35
Interest & Investment Income	16.8	-	-	-	-	-
Currency Exchange Gain (Loss)	-17.1	-	9	-31.3	-	-
Other Non Operating Income (Expenses)	103.51	98.12	2.81	-0.62	-45.19	51.63
EBT Excluding Unusual Items	802.69	-219.02	-466.48	-562.71	-506.15	-348.3
Merger & Restructuring Charges	-	-	-	-	-	-0.3
Gain (Loss) on Sale of Investments	11.83	11.73	-1.98	-17.29	-12.69	33.56
Asset Writedown	-167.93	-168	-217.8	-33.38	-	-54
Other Unusual Items	15.8	12.18	-9.86	25.9	0.5	-33.89
Pretax Income	666.09	-363.12	-696.11	-587.49	-518.34	-402.93
Income Tax Expense	36.91	0.18	-69.51	-28.47	5.56	35.23
Net Income	629.17	-363.3	-626.6	-559.02	-523.9	-438.16
Net Income to Common	629.17	-363.3	-626.6	-559.02	-523.9	-438.16
Shares Outstanding (Basic)	78	77	75	72	70	66
Shares Outstanding (Diluted)	82	77	75	72	70	66
Shares Change (YoY)	7.58%	2.68%	4.33%	1.79%	6.72%	12.17%
EPS (Basic)	8.09	-4.73	-8.37	-7.79	-7.43	-6.64
EPS (Diluted)	7.72	-4.73	-8.37	-7.79	-7.43	-6.64
Free Cash Flow	697.44	-114.19	-186.86	-388.67	-279.55	-211.91
Free Cash Flow Per Share	8.53	-1.49	-2.50	-5.42	-3.97	-3.21
Gross Margin	68.30%	26.64%	21.94%	0.38%	-6.39%	-16.34%
Operating Margin	49.11%	-18.19%	-37.26%	-62.95%	-69.62%	-90.23%
Profit Margin	35.65%	-45.03%	-66.81%	-80.00%	-97.27%	-115.07%
Free Cash Flow Margin	39.52%	-14.15%	-19.92%	-55.62%	-51.90%	-55.66%
EBITDA	894.86	-71.08	-112.81	-311.09	-310.81	-300.09
EBITDA Margin	50.70%	-8.81%	-12.03%	-44.52%	-57.71%	-78.81%
D&A For EBITDA	28.05	75.66	236.59	128.84	64.13	43.49
EBIT	866.81	-146.75	-349.4	-439.93	-374.94	-343.58
EBIT Margin	49.11%	-18.19%	-37.26%	-62.95%	-69.62%	-90.23%
Revenue as Reported	1,765	806.78	937.82	698.8	538.59	380.77

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q